October 28th 2020
Opposing interests make it hard to define what elements are essential for a competitive marketplace.
October 12th 2020
There are diverging opinions on whether comparative efficacy trials add much of value to the evidence for biosimilar approval in the United States.
September 25th 2020
How quickly and easily biosimilars should be declared interchangeable with reference products has been an ongoing issue.
